Ser780

Site Information
AEPtDsDsPPsSsAD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4273912

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:	breast cancer ( 2 , 3 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:	breast ( 1 , 2 ) , HCT116 (intestinal) ( 7 ) , HeLa S3 (cervical) ( 8 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , Jurkat (T lymphocyte) ( 5 , 6 ) , MDA-MB-435S (breast cell) ( 7 ) , MV4-11 (macrophage) ( 7 ) , NCI-H1395 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 4 )

Upstream Regulation
Treatments:	nocodazole ( 8 ) , thymidine ( 8 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Guo A (2011) CST Curation Set: 11847; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
6	Guo A (2011) CST Curation Set: 11849; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738 Curated Info
7	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
8	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info